Baricitinib is a JAK1/2 inhibitor approved for the treatment of active rheumatoid arthritis that was recently approved by FDA for COVID-19 treatment in certain hospitalized adults42, and reported to reduce mortality when administered as monotherapy43 or in combination with remdesivir25. This evidence concerns the gene JAK1 and rheumatoid arthritis.